Delays, bottlenecks and bureaucratic delays have plagued the global introduction of newly approved coronavirus vaccines as it has become apparent that many governments will miss their mass vaccination targets. “fill and finish”fill and finish Other bottlenecks include the willingness of regulatory authorities to authorize packed batches of vaccine, the reliability of national vaccination programs, and local criteria for recipient data counseling, tracking, and subsequent logging, which is generally more time-consuming than injection administration. The United States The implementation of the U.S. vaccination program has slowed, reflecting the tumultuous response of the country under Donald Trump to the pandemic. Of the approximately 17.5 million doses of Pfizer/BioNTech and Moderna vaccines distributed nationally, only 4.2 million have been administered, mainly the first of two doses.
The biggest problem with the delays seems to be the fact that federal officials have left local health departments and hospitals with distribution logistics, even as they have struggled with the repercussions of a pandemic that has killed more than 350,000 Americans already. Nevertheless, Dr. Anthony Fauci, the country’s leading infectious disease expert, said Sunday he had seen a “small glimmer of hope” after 1.5 million doses were given in the past 72 hours – a substantial rise. Israel The Israeli media announced last week that the speed of the vaccine campaign means that purchased doses are running low and that a delay will have to be taken unless a new supply is arranged. “there will be no shortage of the second dose. While the U.K. quickly approved Pfizer/vaccine BioNTech’s for emergency use in the U.K. and has since approved a second dose, the European Medicines Agency has adopted a slower approval process, and since Pfizer/BioNTech is the only vaccine approved in the EU to date, this has led to greater demand from EU countries than the company has been able to supply: “the second dose will not be scarce. Although Pfizer/BioNTech was quickly approved by the U.K. On Monday, in talks with Pfizer and BioNTech, the European Commission announced that it was possible to order more doses of their vaccine, in addition to the 300 million vaccines already covered by an existing contract.
Germany and Denmark are also discussing the possibility of delaying the administration of a second dose of the vaccine to improve tight supplies after the U.K. made a similar move last week. Germany and Denmark are also exploring the possibility of delaying the administration of a second dose of the vaccine to boost tight supplies. France Within the EU, France has its own unique issues that have contributed to poor progress to date in its vaccination program.